The use of patient-reported outcomes to detect adverse events in metastatic melanoma patients receiving immunotherapy: a randomized controlled pilot trial.

ABSTRACT:

Background

A randomized controlled pilot trial was conducted to assess if melanoma patients treated with immunotherapy had the number of grade 3 or 4 adverse events during treatment reduced by 50% using a tailored electronic patient-reported outcomes tool in addition to standard toxicity monitoring compared to standard monitoring alone. Secondary endpoints were: if more AEs were reported in the intervention group, if there was a difference between the two groups in the number of telephone consultations, extra out-patient visits, number of days in the hospital, days in steroid treatment and the time patients experienced grade 2 or higher toxicity.

Patients and methods

Melanoma patients receiving immunotherapy at the Department of Oncology, Odense University Hospital, Denmark

SUBMITTER: Tolstrup LK 

PROVIDER: S-EPMC7599285 | biostudies-literature | 2020 Oct

REPOSITORIES: biostudies-literature